The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors

被引：0
|
作者：
Vladimer Darsalia
Martin Larsson
Thomas Klein
Cesare Patrone
机构：
[1] Karolinska Institutet,Department of Clinical Science and Education, Södersjukhuset, Internal Medicine
[2] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
来源：
Cardiovascular Diabetology | / 17卷
关键词：
Glucagon-like peptide 1 receptor; Dipeptidyl peptidase-4 inhibitors; Stroke; Diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
    Dicembrini, Ilaria
    Pala, Laura
    Rotella, Carlo Maria
    EXPERIMENTAL DIABETES RESEARCH, 2011,
  • [22] The neuroprotective efficacy of the DPP-4 inhibitor linagliptin against stroke is not mediated by GLP-1 receptor activation
    Darsalia, V.
    Larsson, M.
    Nathanson, D.
    Drucker, D. J.
    Nystrom, T.
    Klein, T.
    Patrone, C.
    DIABETOLOGIA, 2015, 58 : S35 - S35
  • [23] The Place of GLP-1-Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists
    Mize, Dara L. Eckerle
    Salehi, Marzieh
    CURRENT DIABETES REPORTS, 2013, 13 (03) : 307 - 318
  • [24] INSULIN IS MOST APPROPRIATE COMPARATOR TO GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS IN REAL-WORLD CARDIOVASCULAR OUTCOME STUDIES
    Ali, A. K.
    Motsko, S. P.
    VALUE IN HEALTH, 2017, 20 (05) : A311 - A311
  • [25] The risk of acute pancreatitis with GLP-1 receptor agonists and DPP-4 inhibitors: a retrospective observational cohort study
    Koro, C. E.
    Sowell, M. O.
    Stender, M.
    Chhabra, P.
    Allen, J. K.
    Krzywy, H. J.
    DIABETOLOGIA, 2013, 56 : S183 - S184
  • [26] Comparative Effectiveness of SGLT-2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists in US Veterans with and Without CKD
    Narasaki, Yoko
    Kovesdy, Csaba P.
    You, Amy S.
    Potukuchi, Praveen Kumar
    Dashputre, Ankur A.
    Sumida, Keiichi
    Thomas, Fridtjof
    Streja, Elani
    Kalantar-Zadeh, Kamyar
    Rhee, Connie
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 264 - 264
  • [27] SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors and Risk of All-Cause Hospitalization
    Lyu, Beini
    Grams, Morgan
    Chang, Alex R.
    Inker, Lesley A.
    Coresh, Josef
    Shin, Jung-Im
    DIABETES, 2021, 70
  • [28] SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists
    Davidson, Mayer B.
    ANNALS OF INTERNAL MEDICINE, 2019, 171 (12) : JC70 - JC70
  • [29] Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
    Sachinidis, Alexandros
    Nikolic, Dragana
    Stoian, Anca Pantea
    Papanas, Nikolaos
    Tarar, Omer
    Rizvi, Ali A.
    Rizzo, Manfredi
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 111
  • [30] Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy
    Takayanagi, Risa
    Uchida, Takumi
    Kimura, Koji
    Yamada, Yasuhiko
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2018, 41 (02) : 153 - 157
12345